This site is intended for health professionals only
Genentech Inc has sent a letter to doctors in the USA, advising them of the results of an interim analysis of a trial of ranibizumab (Lucentis). According to these preliminary results, 1.2% of patients given a 0.5mg dose of the drug suffered a stroke, compared with 0.3% of those given a 0.3mg dose.
According to a company spokesperson, these findings are consistent with data from previous trials. In addition, it appears that patients who had a previous stroke are at greater risk of another stroke.